This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Actinium Pharmaceuticals receives...
Business patent allowance

Actinium Pharmaceuticals receives Canadian patent allowances

Analysis based on 7 articles · First reported May 29, 2026 · Last updated May 29, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The patent allowances for Actinium Pharmaceuticals' Actimab-A and Iomab-ACT programs are expected to positively impact the company's stock price by strengthening its intellectual property and market position. This development signals increased confidence in Actinium Pharmaceuticals' pipeline and future revenue potential within the biotechnology and pharmaceutical industries.

Biotechnology Pharmaceuticals
Event Summary

Actinium Pharmaceuticals announced that the Canada — Canadian Intellectual Property Office has issued Notices of Allowance for two patent applications. These allowances cover the company's Actimab-A program, used in combination with CLAG-M chemotherapy for AML, and its Iomab-ACT program, a targeted CD45 conditioning approach for gene-edited cell-based therapies. This expands Actinium Pharmaceuticals' intellectual property protection in Canada, building on existing patents in Japan and the United States, with further applications pending in the United States, Europe, and China. Adeela Kamal, EVP-R&D of Actinium Pharmaceuticals, highlighted that these allowances reflect the breadth of innovation and commitment to protecting the company's radiotherapy platform globally. The patents are expected to be issued in the ordinary course, reinforcing Actinium Pharmaceuticals' global patent estate of approximately 250 issued and pending patents.

Entities Involved
stock
Actinium Pharmaceuticals
Actinium Pharmaceuticals received two patent allowances from the Canada — Canadian Intellectual Property Office, strengthening its intellectual property protection for its Actimab-A and Iomab-ACT programs. This enhances the company's market position and potential for future revenue.
Importance 100.0 Sentiment 50.0
govactor
Canada — Canadian Intellectual Property Office
The Canada — Canadian Intellectual Property Office issued Notices of Allowance for two patent applications to Actinium Pharmaceuticals, playing a key role in the expansion of Actinium Pharmaceuticals' intellectual property in Canada.
Importance 70.0 Sentiment 0.0
cnt
Canada
Canada is an important market where Actinium Pharmaceuticals has expanded its intellectual property protection through the Canada — Canadian Intellectual Property Office.
Importance 40.0 Sentiment 0.0
cnt
Japan
Japan is a major market where Actinium Pharmaceuticals had previously secured a patent for its Actimab-A program, complementing the recent Canadian allowances.
Importance 20.0 Sentiment 0.0
cnt
United States
The United States is a major market where Actinium Pharmaceuticals had previously secured a patent for its Iomab-ACT program and has additional applications pending.
Importance 20.0 Sentiment 0.0
per
Adeela Kamal
Adeela Kamal, EVP-R&D of Actinium Pharmaceuticals, commented on the significance of the patent allowances for the company's innovation and commitment to intellectual property protection.
Importance 10.0 Sentiment 0.0
loc
Europe
Europe is a region where Actinium Pharmaceuticals has additional patent applications pending for its Actimab-A and Iomab-ACT programs.
Importance 10.0 Sentiment 0.0
cnt
China
China is a major market where Actinium Pharmaceuticals has additional patent applications pending for its Iomab-ACT program.
Importance 10.0 Sentiment 0.0
Relationships
Canada related ↔ Japan
Canada strained-ally ↔ United States Canada faces an unprecedented diplomatic and economic crisis with the United States, characterized by a massive tariff w
Canada related ↔ China
Japan ally ↔ United States Japan relies on the United States as its primary security guarantor and a crucial economic partner, hosting significant
Japan strategic rival ↔ China Japan considers China its greatest strategic challenge, countering Beijing's military assertiveness and economic coercio
United States rivals ↔ China The United States treats China as a major economic and geopolitical adversary, aggressively imposing sweeping tariffs an
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.